Type 2 diabetes is a progressive condition that may require the combination of three oral treatments to achieve optimal glycemic 
INTRODUCTION
Type 2 diabetes is a progressive life-long condition that, if poorly managed, results in significant morbidity as a result of micro-and macrovascular complications [1, 2] . Macrovascular or cardiovascular disease is the leading cause of mortality in individuals with type 2 diabetes, accounting for 54% of deaths [2] . Effective diabetes management to prevent the development of long-term complications requires intensive treatment of numerous risk factors, including hypertension, hypercholesterolemia, and hyperglycemia. In recent years, the treatment options to achieve optimum glycemic control have rapidly expanded. There are currently five groups of oral agents and two injectable therapies available (Fig. 1) . The challenge for clinicians is determining which combination of treatment is most appropriate for an individual with type 2 diabetes, with the recommendation being that a maximum combination of three oral treatments are used [3] . This article does not contain any new studies with human or animal subjects performed by any of the authors. Informed consent was received from all patients for inclusion in this article.
PATHOPHYSIOLOGY
The number of people diagnosed with type 2 diabetes has escalated in the last decade, and is reaching epidemic levels worldwide [4] . In 2014, the worldwide prevalence of diabetes for 20-79 year olds was 387 million, with type 2 diabetes accounting for 90% of cases [2] . This rapid increase in the incidence of diabetes is linked partly to the significant increase in the worldwide population who are overweight or obese. The latter account for 80-85% of those at risk for developing type 2 diabetes [2] , although the aging populations of, in particular, many westernized countries have also contributed to its increased incidence.
The primary pathophysiological abnormality in the majority of individuals that develop type 2 diabetes is insulin resistance. Insulin resistance develops when the insulin receptor on the surface of muscle and other cells change shape. This results in an inability of the insulin molecule to attach to the receptor opening the glucose channel, which prevents the uptake of glucose by the cells. Many ethnic groups have underlying insulin resistance which is significantly increased by any escalation in weight. Type 2 diabetes is six times more common in people of South Asian descent, and three times more common in those of African or African Caribbean origin [2] .
As insulin resistance increases, the beta cells compensate by producing additional insulin which maintains blood glucose levels within Fig. 1 Diabetes treatment tree. GLP1 glucagon-like peptide-1, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU sulfonylurea the normal range. However, with increasing insulin resistance and progressive beta cell failure, blood glucose levels become increasingly difficult to maintain within the normal range of 3.5-6.5 mmol/L. The high demand for insulin and the glucose toxicity that develops from increasing blood glucose levels results in the development of beta cell failure and a decline in insulin production.
Type 2 diabetes is preceded by a period of impaired glucose regulation that can be corrected if the body's insulin requirements are reduced by a reduction in weight, increase in physical activity, or reduction in food intake, or a combination of all three. Type 2 diabetes develops when an individual's demand for insulin exceeds the amount they are able to produce, even though at the time of diagnosis they may have significant hyperinsulinemia.
Beta cell failure is also linked to increasing age, and when type 2 diabetes develops in an elderly person with a healthy body mass index (BMI) the underlying cause is most likely beta cell failure.
Insulin release occurs in two phases. First-phase insulin release occurs 2-10 min following a rise in blood glucose level; this rapid release of insulin prevents the blood glucose level from rising too high.
Second-phase insulin release is much more controlled. The amount and speed of insulin release is determined by the actual rise in blood glucose level and the rate that carbohydrate is digested. First-phase insulin release is stimulated by the hormone glucagon-like peptide-1 (GLP-1), which primes the beta cells in the pancreas to release insulin in response to a rise in the blood glucose level. GLP-1 is rapidly destroyed in the body by the enzyme dipeptidyl peptidase-4 (DPP4), and has a half-life of 2 min. First-phase insulin release is absent in type 2 diabetes as a result of low levels of the GLP-1 hormone.
In a healthy individual, glucose should not be present in the urine. As blood passes through the kidney, all glucose passes through the glomerulus into the nephric filtrate; 100% of glucose, 99% of water, and other essential electrolytes are reabsorbed through a process of selective reabsorption as the filtrate passes through the nephron. Glucose reabsorption occurs predominantly (90%) in the proximal tubule due to the action of the hormone sodium-glucose co-transporter 2 (SGLT2), which opens glucose channels in the wall of the tubule. A normal renal threshold enables 10 mmol/L of glucose to be reabsorbed with water reabsorption occurring through osmosis in the loop of Henle. If blood glucose levels in the filtrate exceed the renal threshold, glucose will remain in the filtrate and result in reduced water reabsorption and the presence of glucose in the urine.
LITERATURE REVIEW
The publication of the UK Prospective Diabetes Study (UKPDS) [5] brought into question the importance of glycemic management in the prevention of macrovascular complications in type 2 diabetes. The impact of intensive glycemic control on the prevention of macrovascular disease, unlike in microvascular disease, did not reach statistical significance. The focus changed to intensive blood pressure management. However, the publication of the UKPDS follow-on study [1] [3, 7] , and are supported by the development of treatment plans that utilize a combination of treatments which take into consideration age, occupation, and estimated glomerular filtration rate (eGFR) to achieve agreed individualized targets.
Treatment Options

Biguanides
Metformin is the only biguanide available, and one of the oldest treatments for diabetes, dating response is noted with 45 mg, the dose should be reduced back to 30 mg [9] . If a 6 mmol/mol severe and disabling joint pain. It was found that when DPP4 inhibitors were stopped, the pain and symptoms resolved. Therefore, it would be appropriate to consider a trial without the DPP4 inhibitor if patients report joint pains [11] . Concerns relating to DPP4 inhibitors and increased heart failure risk have been raised in cardiovascular safety studies for a number of treatments. The SAVOR-TIMI 53 trial [12] found an increased risk of admission to hospital for heart failure with saxagliptin. The EXAMINE trial [13] , which reviewed alogliptin, and the TECOS trial [14] , which reviewed sitagliptin, did not identify any statistically significant effect on hospital admissions for heart failure. More recently, a further safety review from the US Food and Drug
Administration [15] found that saxagliptin and alogliptin may increase the risk of heart failure, especially in patients where heart failure or kidney disease is already present. Patients therefore should be warned of the signs and symptoms of heart failure and advised to seek urgent medical advice if concerned, and healthcare professionals should contemplate stopping the treatment if patients develop heart failure. Applying these findings to clinical practice would mean exercising caution when utilized in patients with type 2 diabetes with heart and kidney disease, paying particular attention to ensuring correct dosage based on a current eGFR result. Response to treatment initiation must be reviewed, and if the HbA1c has not reduced by 6 mmol/mol from when the treatment was initiated it should be discontinued [3] .
SGLT2 Inhibitors
These are the newest group of oral hypoglycemic agents, and include dapagliflozin, canagliflozin, and empagliflozin. SGLT2 is a protein which encourages glucose reabsorption in the proximal tubule in the kidney. The SGLT2 inhibitors block the receptor site, preventing activation of the glucose channel and glucose reabsorption, so the glucose remains in the renal filtrate and ultimately the urine. As the filtrate passes through the loop of Henle, water is reabsorbed by osmosis, but as a result of the elevated levels of glucose in the filtrate, reduced water reabsorption occurs, resulting in increased urine production. The loss of glucose in the urine and thus calories can result in weight loss.
However, the side effects due to the glycosuria include increased risk of urinary tract infections and thrush/balanitis. For SGLT2 inhibitors to be effective, good renal function is required, and they should not be prescribed to patients whose eGFR is less than 60 mL/min/ As with all new diabetes oral therapies, they require the study of cardiovascular endpoints to assess safety. Empagliflozin, the most recent SGLT2 inhibitor on the market, was found to have added benefits of reducing the relative risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 14% and a significant 38% relative risk reduction in cardiovascular death rate. These positive results come from the EMPA-REG OUTCOME trial [16] , but it still needs to be determined if this relates to the class of drugs, as cardiovascular outcome studies are still in progress for canagliflozin and dapagliflozin.
A number of clinical concerns have been raised with this group of drugs. An increased risk of acidosis with euglycemia has been noted, particularly during the first 2 months of treatment [17] . Whilst the case numbers were low and a third were identified as having type 1 diabetes, clear guidance has been issued thatparticularly when used in combination with insulin or a sulfonylurea, where doses have been reduced-vigilance for ketosis must be high.
Patients therefore should be informed of the signs and symptoms of diabetic ketoacidosis (DKA), and healthcare professionals still need to consider DKA in patients who present with the symptoms but whose glucose levels are within the normal range and, as with metformin treatment, should be suspended in patients hospitalized for major surgical procedures or acute medical illness and restarted once the patient's condition has stabilized.
Concerns in relation to an increased frequency of fractures with canagliflozin compared to placebo and links to reduced bone mineral density have resulted in changes to the drug label ''warning and precaution'' and ''adverse reactions'' [18] ; further concerns have been highlighted in the CANVAS study in relation to increased amputation rates in those patients with a high cardiovascular risk, particularly those with a previous history of amputation [20] . In clinical practice, this requires healthcare professionals to be mindful of patient risk factors before commencing this treatment, and to consider if it actually the most appropriate treatment choice for that patient. Reporting side effects is an important way of establishing any adverse impacts from new drugs, and all healthcare professionals need to be involved in this process when appropriate. The importance of ensuring that patients maintain good levels of hydration when treated with SGLT2 inhibitors in order to minimize the risk of potential adverse outcomes is being increasingly being stressed [20] . would be an option for third-line therapy. Table 3 shows the treatment decisions and rationales for this patient. Pioglitazone has the potential to improve his insulin sensitivity. A SGLT2 inhibitor will potentially result in weight loss, and a 5-10% weight loss would have a positive impact on insulin sensitivity. As the patient is an occupational driver with potentially erratic meal patterns, it is important to minimize the risk of hypoglycemia. Whichever treatment is commenced first should be agreed upon following discussion with the patient. The unused treatment should be added if triple therapy is indicated or the first choice is stopped due to lack of impact on control or side effects. Table 4 shows the treatment decisions and rationales for this patient.
CASE STUDIES
Case Study 4
A 68-year-old female newly diagnosed with diabetes from a random blood glucose level of 
Treatment Recommendation
Glimepiride with blood glucose self-monitoring to facilitate dose titration. A sulfonylurea will have the quickest impact on symptoms, as it will stimulate increased insulin production if sufficient beta-cell function remains. Blood glucose self-monitoring will be required to facilitate rapid dose titration to correct high blood glucose levels and in turn resolve symptoms. If there is no response to glimepiride in the first couple of weeks, rapid referral to the specialist diabetes team for insulin therapy is indicated. Metformin could be added as second-line treatment if there is a 
